Luc F. Van Gaal

Q: What Schools Are Affiliated With Luc F. Van Gaal

Luc F. Van Gaal is affiliated with the following schools: University of Antwerp

Luc F. Van Gaal's AcademicInfluence.com Rankings

Luc F. Van Gaal

Philosophy

#11499

World Rank

#15838

Historical Rank

Logic

#8304

World Rank

#10371

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Luc F. Van Gaal's Degrees

PhD Biomedical Sciences University of Amsterdam
Doctorate Medicine University of Amsterdam

Why Is Luc F. Van Gaal Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Luc F. Van Gaal's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study (2005) (1354)
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial (2018) (993)
Effect of sibutramine on weight maintenance after weight loss: a randomised trial (2000) (861)
Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study (2009) (801)
Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study (2006) (725)
Dysfunction of lipid sensor GPR120 leads to obesity in both mouse and human (2012) (573)
Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial (2010) (429)
3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial (2017) (406)
Assessing the impact of complications on the costs of Type II diabetes (2002) (366)
Depot-Specific Differences in Adipose Tissue Gene Expression in Lean and Obese Subjects (1998) (365)
Obesity, haemostasis and the fibrinolytic system (2002) (343)
Environmental pollutants and type 2 diabetes: a review of mechanisms that can disrupt beta cell function (2011) (233)
Preventive cardiologyAbstractEffects of the Cannabinoid-1 Receptor Blocker Rimonabant on Weight Reduction and Cardiovascular Risk Factors in Overweight Patients: 1-Year Experience From the RIO-Europe Study (2005) (179)
A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects (2004) (154)
Autoimmune gastritis in type 1 diabetes: a clinically oriented review. (2008) (92)
What is the relationship between risk factor reduction and degree of weight loss (2005) (88)
Association of SIRT1 gene variation with visceral obesity (2008) (87)
The Effect of Weight Loss on Sleep-Disordered Breathing in Obese Teenagers. (2009) (81)
Relationship between HbA1c levels and risk of cardiovascular adverse outcomes and all-cause mortality in overweight and obese cardiovascular high-risk women and men with type 2 diabetes (2012) (74)
Recommendations for the nutritional management of patients with diabetes mellitus† (2000) (72)
Relationship of Body Fat Distribution Pattern to Atherogenic Risk Factors in NIDDM: Preliminary Results (1988) (72)
The Effect of Weight Loss on Sleep‐disordered Breathing in Obese Teenagers (2009) (69)
The G1422A variant of the cannabinoid receptor gene (CNR1) is associated with abdominal adiposity in obese men (2007) (64)
Impact of Overweight on Chronic Microvascular Complications in Type 1 Diabetic Patients (2005) (60)
"CENTRAL OBESITY" AND CORONARY HEART DISEASE (1987) (56)
Rationale and options for combination therapy in the treatment of Type 2 diabetes (2003) (52)
Drug-induced obesity and its metabolic consequences: a review with a focus on mechanisms and possible therapeutic options (2017) (49)
Are leptin levels dependent on body fat distribution in obese men and women? (1998) (44)
Body mass index and health among the working population- Epidemiologic data from Belgium (1999) (39)
Overweight, obesity, and outcomes: fat mass and beyond (2014) (37)
Is sleep-disordered breathing an additional risk factor for the metabolic syndrome in obese children and adolescents? (2009) (35)
Long-term health considerations in schizophrenia: Metabolic effects and the role of abdominal adiposity (2006) (33)
GLP-1 receptor agonists for type 2 diabetes (2009) (33)
Sleep-disordered breathing: a new risk factor of suspected fatty liver disease in overweight children and adolescents? (2008) (31)
Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension (2022) (31)
Serum and erythrocyte magnesium levels in type I and type II diabetics (1985) (29)
Screening for melanocortin-4 receptor mutations in a cohort of Belgian morbidly obese adults and children (2006) (25)
Sex- and season-dependent differences in C-peptide levels at diagnosis of immune-mediated type 1 diabetes (2006) (23)
Effect of rimonabant on weight reduction and cardiovascular risk (2005) (23)
Relation between disease phenotype and HLA-DQ genotype in diabetic patients diagnosed in early adulthood (2002) (21)
Tolerability of Sibutramine During a 6-week Treatment Period in High-Risk Patients With Cardiovascular Disease and/or Diabetes: A Preliminary Analysis of the Sibutramine Cardiovascular Outcomes (SCOUT) Trial (2008) (21)
Sleep-disordered breathing and C-reactive protein in obese children and adolescents (2013) (20)
Repaglinide improves blood glucose control in sulphonylurea-naive type 2 diabetes. (2001) (19)
Bariatric surgery to treat type 2 diabetes: what is the recent evidence? (2012) (17)
Carbohydrate-induced thermogenesis in obese women. Effect of insulin and catecholamines (1999) (17)
Cost Effectiveness of Atorvastatin in Patients with Type 2 Diabetes Mellitus (2010) (16)
Possible role for ENPP1 polymorphism in obesity but not for INSIG2 and PLIN variants (2009) (16)
Drugs That Affect Body Weight, Body Fat Distribution, and Metabolism (2019) (16)
Lixisenatide Treatment for Older Patients with Type 2 Diabetes Mellitus Uncontrolled on Oral Antidiabetics: Meta-Analysis of Five Randomized Controlled Trials (2014) (15)
Efficacy and safety of the weight-loss drug rimonabant (2008) (13)
Effects of initial BMI and on-treatment weight change on the lipid-lowering efficacy of fibrates (1997) (13)
Incidence and predisposing factors for the development of disturbed glucose metabolism and diabetes mellitus after intensive care admission: the DIAFIC study (2015) (12)
35th Annual meeting of the European Association for the Study of Diabetes. Brussels, Belgium, 28 September-2 October, 1999. Abstracts. (1999) (11)
Recent and Future Drugs for the Treatment of Obesity (2002) (7)
Reduction in the risk of developing type 2 diabetes (T2D) with liraglutide 3.0 mg in people with prediabetes from the SCALE Obesity and Prediabetes randomized, double-blind, placebo-controlled trial (2016) (7)
We-W42:3 Rimonabant improves cardiometabolic risk factors in overweight/obese patients irrespective of treatment with statins: Pooled data from the RIO program (2006) (6)
Vitamin E status in normocholesterolemic and hypercholesterolemic diabetic patients (1987) (6)
EFFECTS ON MORTALITY AND MORBIDITY IN OVERWEIGHT/OBESE SUBJECTS: THE SIBUTRAMINE CARDIOVASCULAR OUTCOMES (SCOUT) TRIAL (2010) (6)
Mutation analysis of WNT10B in obese children, adolescents and adults (2013) (5)
Liraglutide for weight loss in obese people – Authors' reply (2010) (5)
Reducing cardiovascular risk in patients with type 2 diabetes: the potential contribution of nicotinic acid (2005) (5)
Hyperkalemia in Diabetic Ketoacidosis (1981) (4)
Reverse T3 changes during protein supplemented diets. Relation to nutrient combustion rates (1989) (4)
The Once-Daily Human GLP-1 Analog Liraglutide Reduces the Prevalence of Prediabetes and Improves Systolic Blood Pressure in Obese Non-Diabetic Subjects: A 52-Week, Randomized Placebo-Controlled Trial (2009) (4)
Roux-en-Y gastric bypass, but not sleeve gastrectomy, decreases plasma PCSK9 levels in morbidly obese patients. (2020) (4)
AN ENDOCRINE PICTURE IN DISGUISE: A PROGRESSIVE OLFACTORY NEUROBLASTOMA COMPLICATED WITH ECTOPIC CUSHING SYNDROME (2017) (3)
Human obesity: a medical assessment of health risks. (1995) (3)
Erratum: Relationship between HbA 1c levels and risk of cardiovascular adverse outcomes and all-cause mortality in overweight and obese cardiovascular high-risk women and men with type 2 diabetes (Diabetologia DOI 10.1007/s00125-012-2584-3) (2012) (3)
35th Annual Meeting of the European Association for the Study of Diabetes (2016) (3)
The effect of semaglutide on liver enzymes in subjects with obesity and elevated alanine aminotransferase: Data from a randomised Phase 2 trial (2018) (3)
Effects of lipid-lowering drugs on the in vitro oxidizability of lipoproteins in diabetes (1996) (3)
Effects of smoking on lipid parameters during therapeutic weight loss (1986) (3)
Does pharmacotherapy have a place in the weight management of patients with type 2 diabetes (2010) (2)
Glycaemic and blood pressure control seems harder to improve than lipid control in type 2 diabetic patients: comparison of two surveys over 5 years in Belgium. (2008) (2)
1.3 Exenatide Once Weekly: Sustained Glycemic and Weight Control Through 3 Years Compared with Insulin Glargine (67-OR) (2013) (2)
A-2b and Zinc Transporter 8 to Classification of Diabetes Diagnosed Under 40 Years of Age (2011) (2)
Body fat mass distribution. Influence on metabolic and atherosclerotic parameters in non-insulin dependent diabetics and obese subjects with and without impaired glucose tolerance. Influence of weight reduction. (1989) (2)
Assessment and Investigation of Obesity (2009) (2)
Liraglutide, a once-daily human GLP-1 analogue, reduces the prevalence of prediabetes in obese subjects over 20 weeks: a randomized placebo-controlled trial (2009) (2)
Effects of canagliflozin versus glimepiride on adipokines, inflammatory biomarkers, and chemokines in patients with type 2 diabetes mellitus (2017) (2)
Erratum: Early response to sibutramine in patients not meeting current label criteria: Preliminary analysis of SCOUT lead-in period (Obesity 18 (987-994) DOI: 10.1038/oby.2009.327) (2010) (2)
Sleep-disordered breathing and adipokine secretion in obese children and adolescents (2015) (2)
Treatment with Liraglutide, a Once-Daily Human GLP-1 Analog, for 52 Weeks Reduces Weight and Waist Circumference: A Randomized Placebo-Controlled Trial (2009) (2)
Predictors of Insulin Resistance in Obesity and Type 2 Diabetes Mellitus - The Role of Magnesium (2017) (1)
Reply to “Is there a clear link between overweight/obesity and sleep disordered breathing in children?” (2008) (1)
Impedance measurements of fatfree mass are influenced by changes of extracellular fluids (1990) (1)
Rimonabant improves cardiometabolic risk factors in overweight/obese patients with poorly controlled type 2 diabetes (HbA (1c)>= 8%) on monotherapy with metformin or sulfonylureas (2006) (1)
Rimonabant improves multiple cardiometabolic risk factors in diabetic and non-diabetic overweight/obese patients: data from RIO-diabetes, RIO-Europe, RIO-North America and RIO-Lipids (2006) (1)
Are sex hormones involved in resting metabolic rate and glucose-induced thermogenesis? A study in obese men and women (1991) (1)
Reducing cardiometabolic risk through selective antagonism of CB1 receptors. (2007) (1)
Plasma glucagon levels in upper body obesity: glucagon-lipid interactions (1991) (1)
Magnesium Status during Dietary Treatment of Obesity (1985) (1)
Efficacy and safety of exenatide once weekly: an overview of the DURATION trials (2012) (1)
Impact of exenatide once weekly and insulin glargine on glucose control and cardiovascular risk factors in subjects with type 2 diabetes (2010) (1)
Glycemic Target Attainment in Insulin-Naïve Patients with T2D Receiving iGlarLixi (2018) (1)
Drugs That Modify Fat Absorption and Alter Metabolism (2003) (1)
Sleep-disordered breathing and the metabolic syndrome in children and adolescents (2009) (1)
Insulinoma in the elderly : a report of three cases and review literature (2014) (1)
1020-P: Semaglutide-Induced Weight Loss Is Associated with Improved Health-Related Quality of Life and Treatment Satisfaction (2019) (1)
Haemostasis and visceral fat (1999) (1)
Taking Action on Excess Visceral Fat (2012) (0)
Update on obesity : symposium of the Belgian Association for the Study of Obesity, 11 March 1995, Brussels, Belgium (1995) (0)
Analysis of low density lipoprotein receptor gene mutations in Belgians with type IIA hyperlipidemia (1995) (0)
6.3 Efficacy and Safety of Lixisenatide in Elderly T2DM Patients: Subanalysis from the GetGoal Program (916-P) (2013) (0)
Adipokines in obese children and adolescents with sleep-disordered breathing (2012) (0)
Abstract 17101: Vasoprotective Properties of HDL Improve Early Ater Roux-en-y Gastric Bypass but Not After Diet Treatment: The Superior Cardiometabolic Benefits of RYGB (2015) (0)
Effect of weight reduction on blood viscosity parameters in obese women (2016) (0)
Is age a factor for blood-pressure and weight-loss changes during sibutramine treatment? A preliminary analysis of the sibutramine cardiovascular outcomes (SCOUT) trial (2008) (0)
Nephrology Dialysis Transplantation Elevated plasminogen activator inhibitor levels in cyclosporin-treated renal allograft recipients (2005) (0)
70 Human obesity: from lipid abnormalities to lipid oxidation (1997) (0)
MS258 CONSENSUS ON EARLY MANAGEMENT OF FAMILIAL HYPERCHOLESTEROLEMIA IN BELGIUM (2010) (0)
The role of nocturnal pulse oximetry in the screening for obstructive sleep apnea in obese children and adolescents (2015) (0)
doctors on the front line Time for a civilian front line ? (2010) (0)
Weight loss induced by semaglutide once weekly contributes to improved health-related quality of life and treatment satisfaction (2019) (0)
Improved cardiovascular and renal outcomes in the CANVAS Program irrespective of baseline body mass index (2018) (0)
Journal Scan-Type 2 Diabetes CME (2006) (0)
The Effects Of Weight Loss And Sleep-disordered Breathing On Systemic Inflammation And Oxidative Stress In Childhood Obesity (2010) (0)
Effects of treatment with liraglutide 3.0 mg in subjects with BMI < 35 and BMI ≥35 kg/m2: subgroup analysis of the SCALE Obesity and Prediabetes 56-week trial (2016) (0)
Clinical Importance of One-Hour Plasma Glucose in Relation to Diabetes and Metabolic Syndrome in an Obese Population (2018) (0)
EE5 COST-EFFECTIVENESS OF ATORVASTATIN IN TYPE 2 DIABETES PATIENTS: A PHARMACO-ECONOMIC ANALYSIS OF THE COLLABORATIVE ATORVASTATIN DIABETES STUDY (CARDS) IN THE BELGIAN POPULATION (2008) (0)
Changes in Body Weight and Pulse: Outcome Events in Overweight and Obese Subjects with Cardiovascular Disease (2014) (0)
Glycaemic control and blood pressure control seems harder to imporve than lipid control in Type 2 Diabetic Patients: Comparison of two Surveys over 5 Years (2008) (0)
Perioperative parenteral nutrition in the stressed diabetic patient (1986) (0)
EFFECTS OF CANAGLIFLOZIN VERSUS GLIMEPIRIDE ON INFLAMMATORY BIOMARKERS AND CHEMOKINES IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (2017) (0)
ABDOMINAL OBESITY, DYSLIPIDEMIA, INSULIN RESISTANCE, TYPE 2 DIABETES AND ATHEROSCLEROSIS: WHO IS THE RIGHT PATIENT TO BE TREATED WITH CB1 RECEPTOR ANTAGONISTS? (2008) (0)
Additive effects of weight loss and sibutramine in managing hypertensive patients - An analysis of the sibutramine cardiovascular outcomes (SCOUT) trial (2007) (0)
Can long term magnesium supplementation stabilize the progressin of diabetic retinopathy in magnesium-depleted type 1 diabetic patients? (2006) (0)
Hyperinsulinism, insulin resistance and syndrome X (1994) (0)
Reply to letter by Forbes (1986) (0)
Rimonabant improves glucose tolerance in the overweight or obese non-diabetic patient: analysis of the RIO-Europe and RIO-Lipids studies (2007) (0)
Effects of hypolipidemic drugs on the in vitro oxidizability of non-HDL lipoproteins in insulin-dependent diabetic patients with incipient nephropathy (1994) (0)
Importance of obesity as a cardiovascular risk factor: from total to central body fat (1992) (0)
CB1 Antagonism in the Management of Abdominal Obesity (2008) (0)
Abstracts of the meeting of the Belgian Society of Internal Medicine (13 May 1995) (1995) (0)
Rimonabant Appears to Reduce Risk for Diabetes Complications (2006) (0)
Two novel frameshift mutations in the LDL-receptor gene generated by endogenous sequence-directed mechanism (1995) (0)
Two novel frameshift mutations in the low density lipoprotein receptor gene generated by endogenous sequence-directed mechanisms (1995) (0)
P.53 Refeeding in anorexia nervosa (1983) (0)
Mode of action of obesogenic environmental chemicals: An omics approach (2011) (0)
Sleep loss and weight gain (2012) (0)
Erratum to: Relationship between HbA1c levels and risk of cardiovascular adverse outcomes and all-cause mortality in overweight and obese cardiovascular high-risk women and men with type 2 diabetes (2012) (0)
5 Diabetes mellitus en het metabool syndroom (2008) (0)
Oxidative stress in obese children with sleep-disordered breathing (2011) (0)
Efficacy and Safety of Lixisenatide in Elderly Type 2 Diabetes Mellitus Patients: Subanalysis from the GetGoal Program (2013) (0)
Intensive insulin therapy in the intensive care unit : Assessment by continuous glucose monitoring. Authors' reply (2006) (0)
Microalbuminuria in human obesity: role of body composition, hyperinsulinaemia and hyperglycaemia (1997) (0)
Evolution of blood glucose, lipids and oxidative stress status in the postprandial and postabsorptive phases in type 1 diabetes mellitus (2004) (0)
Upper body fat predominance: an endocrine and metabolic chaos. (1991) (0)
Rimonabant in obese patients with type 2 diabetes – Authors' reply (2007) (0)
Improved Cardiovascular and Renal Outcomes in the CANagliflozin CardioVascular Assessment Study (CANVAS) Program Irrespective of Baseline (BL) Body Mass Index (BMI) (2018) (0)
Long-term outcome of placental-site trophoblastic tumours (2009) (0)
Sleep-disordered breathing and metabolic dysregulation in obese children before and after weight loss (2012) (0)
Adiponectin levels decrease before clinical onset of type 1 diabetes but do not improve disease prediction in antibody-positive relatives (2007) (0)
Endothelial protective properties of HDL improve early after roux-en-y gastric bypass but not after diet-induced weight loss: the superior cardiometabolic benefits of RYGB (2016) (0)
Screening for genetic and structural variation in the NPY2R gene in obese children and adolescents (2015) (0)
Rimonabant in overweight/obese patients (2017) (0)
CB1Antagonism in the Management of Abdominal Obesity (2008) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Luc F. Van Gaal?

Luc F. Van Gaal is affiliated with the following schools:

University of Antwerp